MetLife, Inc. research snapshot
MET AI stock analysis reads MetLife, Inc. as a diversified global insurer and employee benefits franchise that posted broad-based Q1 2026 adjusted earnings growth, a 17% adjusted ROE at the top of its target range, active share repurchases, and a rising dividend. At the August 2, 2026 data cutoff, MET traded near $96.13 based on the July 31, 2026 close, with a verified market capitalization near $61.85 billion. The favorable signal is momentum across Group Benefits, Retirement and Income Solutions, Asia, Latin America, EMEA, and MetLife Investment Management. The caution is that consensus analyst price targets average only about $97.75, close to the current price, and the stock is near its 52-week high, so the margin of safety is limited unless Q2 2026 earnings, due August 5, confirm the trend. This MET AI stock analysis is informational research, not investment advice.
Current price
$96.13
Market cap
$61.85 billion
AI score
75 / 100
Rating
Profitable global insurer with broad Q1 2026 adjusted earnings growth and strong capital return, but analyst price targets sit close to the current price and the stock is near a 52-week high
Trend status
Bullish above the 50-day and 200-day moving averages, with price near the top of the 52-week range
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | MetLife sells life insurance, employee benefits, annuities, retirement income products, and asset management services where customers pay for risk transfer, income protection, savings, and institutional investment expertise. | High |
| Moat | The moat comes from brand, employer distribution, regulatory licenses, actuarial data, global scale, long-term customer relationships, investment management capabilities, and capital strength. | Medium-high |
| Management | Michel Khalaf has led disciplined capital allocation under the New Frontier plan, returning about $1.1 billion to shareholders in Q1 2026, raising the dividend 4.4%, issuing $1 billion of subordinated debt, and integrating PineBridge while keeping the RBC ratio above target. | Medium-high |
| Financial trend | Q1 2026 adjusted earnings rose 18% to $1.6 billion and adjusted EPS rose 23% to $2.42, with revenue up 2.7% to $19.07 billion and net income up about 30% to $1.14 billion. | High |
| Valuation | At $96.13, financial_rigor.py calculates 18.63x trailing EPS of $5.16, about 9.76x expected 2026 EPS of $9.85, 2.27x book value per share of $42.30, 0.80x revenue per share, and a 2.47% dividend yield. | Medium-high |
| Technical trend | MET traded above the 50-day moving average near $88.47 and 200-day moving average near $79.72, with RSI near 65.68 and a July 31 close near the 52-week high of $97.80. | Medium-high |
| Risk level | Main risks are investment losses, commercial mortgage credit, private equity return normalization, rate shocks, underwriting misses, reserve assumptions, foreign currency, regulation, and valuation compression. | Medium-high |
| AI confidence | High for descriptive and reported data. Medium for the forecast because insurance stocks can rerate quickly when rates, credit spreads, equity markets, or actuarial assumptions change. | High data confidence |
| Investment certainty | Medium certainty. MET is a well-disclosed global insurer with improving adjusted earnings, but the stock already reflects a stronger capital-return and earnings story and trades near a 52-week high. | Medium |
MET AI stock forecast
The MET AI stock forecast uses scenario math around the $96.13 quote and 2026 expected adjusted EPS of $9.85. A three-year framework audited with financial_rigor.py produced a bullish value near $157, a base value near $121, and a bearish value near $73 before dividends. These are scenario outputs, not a reliable prediction of MetLife stock price.
$150 to $162
More likely if adjusted EPS compounds near high single digits to double digits, private equity and investment income remain supportive, Group Benefits and Asia keep growing, buybacks reduce share count, and investors value MET near 12x forward earnings.
$115 to $126
More likely if EPS grows near a mid single digit to low double digit pace, adjusted PFO growth stays positive, capital returns continue, credit losses remain manageable, and the market applies about 10x forward earnings.
$70 to $77
More likely if investment losses widen, credit stress rises in mortgage or private assets, variable investment income normalizes lower, underwriting assumptions disappoint, or investors compress MET toward 7x forward earnings.
MET AI technical analysis
MET AI technical analysis was bullish as of the August 2, 2026 data cutoff, but the stock sits near a 52-week high rather than an early low-risk entry. StockAnalysis listed a July 31, 2026 price of $96.13, 50-day moving average near $88.47, 200-day moving average near $79.72, RSI near 65.68, and 20-day average volume near 3.71 million shares. The next earnings report is scheduled for August 5, 2026. Because this static page does not fetch live data, confirm all levels on a current chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $96.13 | July 31, 2026 close used for this static page and market cap verification. |
| Near support | $88 to $89 | The 50-day moving average zone is the first trend support area after the move near the high. |
| Secondary support | $79 to $80 | The 200-day moving average zone is the main long-term trend support reference. |
| Near resistance | $97 to $98 | The 52-week high zone near $97.80 defines the near-term resistance for the stock. |
| 50-day moving average | $88.47 | StockAnalysis moving-average snapshot at the cutoff. |
| 200-day moving average | $79.72 | Price was above this long-term moving average, supporting a positive primary trend. |
| Momentum | RSI 65.68 | Momentum was strong but below the overbought line, which supports the trend while leaving pullback risk. |
| Volume | About 3.71 million shares | 20-day average volume from StockAnalysis. |
| Volatility | Beta 0.78 | StockAnalysis listed a five-year beta below the market, but insurer-specific events can still move the stock sharply. |
| Invalidation | Close below $88, then $80 | A close below the 50-day area weakens the near-term setup. A break below the 200-day area would challenge the primary trend. |
MET AI trading strategy
The MET AI trading strategy is a rules-based framework for a global life insurer and benefits company, not personalized advice. It combines live chart confirmation with earnings quality, adjusted PFO growth, investment income, capital return, book value, and credit-risk monitoring, with the Q2 2026 report on August 5 as the near-term catalyst.
Watch for MET to hold above the $88 area and extend above the $97 to $98 high zone with stronger than average volume, while financial-sector breadth and insurer peer performance remain supportive.
A failed breakout or daily close below the 50-day moving average zone should reduce confidence in the near-term trend setup.
If MET pulls back toward $88 or the $79 to $80 area without deterioration in adjusted earnings, credit marks, holding company liquidity, dividend capacity, or management guidance, compare the pullback with the long-term franchise thesis.
Do not average down solely because MET is a large insurer. Long-duration liabilities, credit marks, and rate shocks can change the equity story quickly.
Track Q2 2026 earnings on August 5, adjusted EPS, adjusted PFO growth excluding pension risk transfers, net investment income, variable investment income, book value per share, adjusted ROE, share repurchases, dividend policy, mortgage loan ACL, and management comments on New Frontier targets.
Lower the rating if adjusted earnings depend mainly on volatile investment returns, credit losses rise faster than capital buffers, book value weakens, or buybacks slow while valuation stays near recent highs.
Investment research summary
MetLife helps employers, households, retirees, and institutions transfer mortality, morbidity, savings, income, and investment risks that are hard for customers to manage alone.
The moat is brand trust, employer channel access, regulatory licensing, actuarial experience, global scale, investment management depth, data from large policy pools, and customer switching friction in benefits and retirement plans.
The thesis can fail if rates move against liabilities, credit losses rise, private equity returns normalize lower, actuarial assumptions prove too optimistic, regulation limits capital return, or the market stops valuing buybacks and adjusted earnings.
Michel Khalaf and the team should be judged by capital allocation, risk discipline, adjusted ROE, book value growth, dividend coverage, integration of PineBridge, and whether New Frontier targets are met without taking hidden balance-sheet risk.
Insurance demand is durable because aging populations, employer benefits, retirement income needs, and risk transfer remain necessary. The industry is not a simple growth curve because results still depend on rates, capital markets, regulation, underwriting, and credit cycles.
At about 9.76x expected 2026 adjusted EPS and near a 52-week high, MET is priced as a healthy insurer rather than a distressed value stock. Consensus price targets average near $97.75, so margin of safety improves only if the stock pulls back while adjusted earnings, liquidity, dividends, buybacks, and credit quality remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $96.13 close on July 31, 2026 | StockAnalysis MET page | August 2, 2026 |
| Market capitalization | $61.85 billion, verified as $96.13 x 643.44 million shares | financial_rigor.py and StockAnalysis | August 2, 2026 |
| Shares outstanding | 643.44 million | StockAnalysis statistics page | August 2, 2026 |
| FY 2025 revenue | $77.084 billion | Macrotrends and StockAnalysis cross-validation | August 2, 2026 |
| FY 2025 net income | $3.173 billion | Macrotrends and StockAnalysis cross-validation | August 2, 2026 |
| TTM revenue through March 2026 | $77.589 billion, up 5.6% | Macrotrends and StockAnalysis cross-validation | August 2, 2026 |
| Q1 2026 net income | $1.14 billion, or $1.74 per share | Macrotrends and MarketBeat cross-validation | August 2, 2026 |
| Q1 2026 adjusted earnings | $1.6 billion, or $2.42 per share, up 18% and 23% | MarketBeat Q1 2026 earnings report | August 2, 2026 |
| Q1 2026 adjusted ROE | 17%, top end of the 15%-17% target range | MarketBeat Q1 2026 earnings call transcript | August 2, 2026 |
| 2026 expected adjusted EPS used for scenarios | $9.85 per share | StockAnalysis forecast page, S&P Global data | August 2, 2026 |
| Analyst price target | $97.75 average, range $75 to $106 | StockAnalysis forecast page, S&P Global data | August 2, 2026 |
| Holding company cash and liquid assets | $3.9 billion at Q1 2026 quarter end | MetLife Q1 2026 earnings release | August 2, 2026 |
| Common dividend | $0.5925 quarterly dividend declared for Q3 2026, payable September 8, 2026 | MetLife dividend declaration | August 2, 2026 |
| Technical snapshot | 50-day moving average $88.47, 200-day moving average $79.72, RSI 65.68, 20-day average volume 3.71 million | StockAnalysis statistics page | August 2, 2026 |
This MET AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of the stated cutoff date, can be wrong, and should be checked against current filings, live market prices, and your own risk constraints.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
